In the sorafenib/erlotinib arm versus the sorafenib/placebo arm , the overall response rate trended higher ( @ % v @ % , respectively ; P = @ ) , whereas the disease control rate was significantly lower ( @ % v @ % , respectively ; P = @ ) .